Drug Uses

Allegra is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes.

How Taken

Allegra is formulated as a capsule or tablet for oral administration. Allegra is usually taken twice a day, in the morning and the evening. Follow your doctor's instructions. Take each dose with a full glass of water.

Warnings/Precautions

Do not take Allegra if you have ever had an allergic reaction to it. Before taking this medication, tell your doctor if you have any serious illness such as heart, kidney, or liver disease. You may require a dosage adjustment or special monitoring during treatment if you have other illnesses. Allegra is in the FDA pregnancy category C. This means that it is not known whether Allegra will harm an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant. It is also not known whether Allegra passes into breast milk. Do not take Allegra without first talking to your doctor if you are breast-feeding a baby. Allegra is not approved for use by children younger than 6 years of age.

Missed Dose

If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not "double-up" the dose to catch up.

Possible Side Effects

Stop taking Allegra and seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives). Allergic reactions occur only rarely, and other serious side effects are not likely to occur. Some less serious side effects may be more likely to occur. Continue to take Allegra and talk to your doctor if you experience nausea or an upset stomach. Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

Storage

Store Allegra capsules and tablets at controlled room temperature 20-25°C (68-77°F). Foil-backed blister packs containing Allegra capsules and all tablet packaging should be protected from excessive moisture.

Overdose

Symptoms and signs of Allegra overdose are: dizziness, drowsiness, and dry mouth. Seek emergency medical attention.

More Information

Tell your doctor of all nonprescription and prescription medication you may use, especially: MAO inhibitors, certain blood pressure drugs, digoxin, and all adrenaline-like drugs. Report other drugs which affect the heart rhythm. Ask your doctor or pharmacist for more details. Check the labels carefully on all nonprescription products, such as cough-and-cold medicines that contain antihistamines and decongestants. Consult your pharmacist. Do not take Allegra for several days before any allergy testing since test results can be affected. Do not start or stop any medicine without doctor or pharmacist approval.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Allegra at Wikipedia.org and other resources:

ALLEGRA--D 24 HOUR (Fexofenadine Hydrochloride And Pseudoephedrine Hydrochloride) Tablet, Film Coated [Sanofi-Aventis U.S. LLC]
Updated Date: Feb 25, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
Conclusions Clearly, the diagnosis and management of DCIS is highly complex with many unanswered questions, including the fundamental natural history of untreated disease. Because of the noninvasive nature of DCIS, coupled with its favorable prognosis, strong consideration should be given to elimination of the use of the anxiety-producing term "carcinoma" from the description of DCIS. The outcomes in women treated with available therapies are excellent. Thus, the primary question for future research must focus on the accurate identification of patient subsets diagnosed with DCIS, including those persons who may be managed with less therapeutic intervention without sacrificing the excellent outcomes presently achieved. Essential in this quest will be the development and validation of accura...

ALLEGRA-D (Fexofenadine And Pseudoephedrine) Tablet, Extended Release [Bryant Ranch Prepack]
Updated Date: Jan 28, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ALLEGRA D-12 HOUR (Fexofenadine Hcl And Pseudoephedrine Hcl ) Tablet, Extended Release [Caremark L.L.C.]
Updated Date: Jan 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Comorbidity, Hospitalization, and Mortality in COPD: Results from a Longitudinal Study
Abstract  We evaluated comorbidity, hospitalization, and mortality in chronic obstructive pulmonary disease (COPD), with special attention to risk factors for frequent hospitalizations (more than three during the follow-up period), and prognostic factors for death. Two hundred eighty-eight consecutive COPD patients admitted to respiratory medicine wards in four hospitals for acute exacerbation were enrolled from 1999 to 2000 in a prospective longitudinal study, and followed up until December 2007. The Charlson index without age was used to quantify comorbidity. Clinical and biochemical parameters and pulmonary function data were evaluated as potential predictive factors of mortality and hospitalization. FEV1, RV, PaO2, and PaCO2 were used to develop an index of respiratory f...